{"protocolSection": {"identificationModule": {"nctId": "NCT03363373", "orgStudyIdInfo": {"id": "201"}, "organization": {"fullName": "Y-mAbs Therapeutics", "class": "INDUSTRY"}, "briefTitle": "Naxitamab for High-Risk Neuroblastoma Patients with Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone And/or Bone Marrow", "officialTitle": "A Pivotal Phase 2 Trial of Antibody Naxitamab (hu3F8) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients with Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone And/or Bone Marrow"}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Y-mAbs Therapeutics", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "Children and adults diagnosed with high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow will be treated for up to 101 weeks with naxitamab and granulocyte-macrophage colony stimulating factor (GM-CSF). Patients will be followed for up to five years after first dose.\n\nNaxitamab, also known as hu3F8 is a humanised monoclonal antibody targeting GD2", "detailedDescription": "Each patient will receive treatment for up to 101 weeks following the first Naxitamab administration. After the end of trial visit, each patient will enter a long-term follow-up where they will be monitored for up to 5 years after first treatment cycle.\n\nEach investigational cycle is started with 5 days, days -4 to 0, of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) administered at 250 \u00b5g/m2/day in advance of the start of Naxitamab administration. GM-CSF is thereafter administered at 500 \u00b5g/m2/day on days 1 to 5. As standard treatment, Naxitamab is administered at 3 mg/kg/day on days 1, 3, and 5, totalling 9 mg/kg per cycle.\n\nTreatment cycles are repeated every 4 weeks (\u00b11 week) until complete response or partial response followed by 5 additional cycles every 4 weeks (\u00b11 week). Subsequent cycles are repeated every 8 weeks (\u00b12 weeks) through 101 weeks from first infusion at the discretion of the investigator. End of treatment will take place around 8 weeks after the last cycle and thereafter long-term follow-up will continue."}, "conditionsModule": {"conditions": ["Neuroblastoma"], "keywords": ["Antibody, Neuroblastoma, Pediatric, Adult"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "interventionModelDescription": "Patients will receive cycles of GM-CSF and Naxitamab every 4 weeks up to a total of 101 weeks. Safety and efficacy will be investigated with short-term follow-up at minimum 4 weeks after last treatment and with long-term follow-up for up to 3 years after end of treatment visit.", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 122, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "GM-CSF + Naxitamab", "type": "EXPERIMENTAL", "description": "Each investigational cycle is started with 5 days of GM-CSF administered at 250 \u00b5g/m2/day in advance of the start of Naxitamab administration. GM-CSF is thereafter administered at 500 \u00b5g/m2/day on days 1 to 5. As standard treatment, Naxitamab is administered at 3 mg/kg/day on days 1, 3, and 5 totalling 9 mg/kg per cycle. Treatment cycles are repeated every 4 weeks until CR or PR followed by 5 additional cycles every 4 weeks (\u00b11 week). Subsequent cycles are repeated every 8 weeks (\u00b12 weeks) through 101 weeks from first infusion at the discretion of the investigator. After end of treatment patients will enter a long-term follow up for up to 3 years after end of treatment visit.", "interventionNames": ["Biological: GM-CSF + Naxitamab"]}], "interventions": [{"type": "BIOLOGICAL", "name": "GM-CSF + Naxitamab", "description": "Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Humanized IgG1 monoclonal GD2 antibody", "armGroupLabels": ["GM-CSF + Naxitamab"]}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of neuroblastoma as defined per International Neuroblastoma Response Criteria\n* High-risk neuroblastoma patients with either primary refractory disease or incomplete response to salvage treatment (in both cases including stable disease, minor response and partial response) evaluable in bone and/or bone marrow.\n* Life expectancy \u2265 6 months\n\nExclusion Criteria:\n\n* Any systemic anti-cancer therapy, including chemotherapy or immunotherapy, within 3 weeks before 1st dose of GM-CSF\n* Evaluable neuroblastoma outside bone and bone marrow\n* Existing major organ dysfunction \\> Grade 2, with the exception of hearing loss, hematological status, kidney and liver function\n* Active life-threatening infection", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "1 Year", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Joris Wilms", "role": "CONTACT", "phone": "+4570261414", "email": "clinicaltrials@ymabs.com"}]}}, "hasResults": false}